Stock Price
3.02
Daily Change
0.05 1.68%
Monthly
-3.21%
Yearly
106.85%
Q1 Forecast
2.88

Galectin Therapeutics reported $-9.17M in EBIT for its fiscal quarter ending in September of 2023.





Ebit Change Date
AbbVie USD 5.81B 4.36B Dec/2025
Bristol-Myers Squibb USD 3.47B 567M Dec/2025
Galectin Therapeutics USD -9.17M 163K Sep/2023
Gilead Sciences USD 2.96B 551M Dec/2025
Immunic USD -22.81M 756K Jun/2024
Incyte USD 383.88M 47.44M Dec/2025
Merck USD 6.24B 1.32B Dec/2025